Provided by Tiger Trade Technology Pte. Ltd.

Cidara Therapeutics

221.38
0.0000
Volume:- -
Turnover:- -
Market Cap:6.96B
PE:-19.73
High:221.38
Open:221.38
Low:221.38
Close:221.38
52wk High:221.42
52wk Low:15.22
Shares:31.44M
Float Shares:24.87M
Volume Ratio:2.02
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.2200
EPS(LYR):-26.7460
ROE:-68.70%
ROA:-29.35%
PB:16.48
PE(LYR):-8.28

Loading ...

Merck Completes Acquisition of Cidara Therapeutics

Reuters
·
Jan 07

Merck to Complete Acquisition of Cidara Therapeutics

THOMSON REUTERS
·
Jan 07

The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com

Dow Jones
·
Dec 05, 2025

BRIEF-Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News

Reuters
·
Dec 01, 2025

Cidara Therapeutics Inc - Interim Analysis in Q1 2026 to Assess Additional Enrollment Need

THOMSON REUTERS
·
Nov 24, 2025

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

GlobeNewswire
·
Nov 24, 2025

Cidara Therapeutics Q3 Operating Expenses USD 88.628 Million

Reuters
·
Nov 20, 2025

Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era -- Barrons.com

Dow Jones
·
Nov 18, 2025

Cidara Therapeutics Cut to Neutral From Buy by Guggenheim

Dow Jones
·
Nov 18, 2025

Cidara Therapeutics Valuation After Clinical Trial Updates and 110% Weekly Price Surge

Simply Wall St.
·
Nov 18, 2025

Cidara Therapeutics downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
Nov 18, 2025

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

Reuters
·
Nov 17, 2025

Merck Exec Says at This Point Co Does Not Expect Cidara Drug Needs to Go Through Cdc Acip to Be Launched

THOMSON REUTERS
·
Nov 17, 2025

Merck CFO Says Co Believes This Transaction Will Negatively Impact EPS by About 30 Cents in the First 12 Months

THOMSON REUTERS
·
Nov 17, 2025

Merck CEO Says in the Long-Term, Merck Will Be the Manufacturer of the Cidara Drug, and It Will Be at a US Site

THOMSON REUTERS
·
Nov 17, 2025

Merck CFO Says Roughly One-Third of Hit to EPS From Cidara Deal Represents Investment to Advance Cd-388, and the Remainder Is the Assumed Cost of Financing

THOMSON REUTERS
·
Nov 17, 2025

Merck CEO Says Co Sees a Greater Than $5 Billion Non Risk Adjusted Commercial Opportunity From Cidara Therapy

THOMSON REUTERS
·
Nov 17, 2025

RBC Downgrades Cidara Therapeutics to Sector Perform From Outperform But Raises Price Target to $221.50 From $145, Removes Speculative Risk

MT Newswires Live
·
Nov 17, 2025

U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior Living

Reuters
·
Nov 17, 2025

Deals of the day-Mergers and acquisitions

Reuters
·
Nov 15, 2025